The key companies such as Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others are involved in developing drugs for Non-Alcoholic Steatohepatitis.
The Non-Alcoholic Steatohepatitis report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The report also highlights the unmet needs concerning the development of Non-Alcoholic Steatohepatitis.
Some of the key highlights of the Non-Alcoholic Steatohepatitis Pipeline Report–
Request for Sample @ Non-Alcoholic Steatohepatitis Pipeline Insights
Non-Alcoholic Steatohepatitis Overview
Non-Alcoholic Steatohepatitis, liver inflammation, and damage caused by a buildup of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) is an umbrella term for a range of liver conditions. The more severe form of NAFLD is called nonalcoholic steatohepatitis (NASH).
NASH Emerging Therapy: Drug Profile
MGL-3196: Madrigal Pharmaceuticals
Resmetirom neither suppresses the central thyroid axis nor THR-α effects on heart rate or bone, and it reduces elevated liver enzymes in NASH patients. Madrigal Pharmaceuticals plans to submit a marketing approval application in Non-alcoholic steatohepatitis to the US FDA.
Know More Information @ NASH Pipeline Drugs
Key Pipeline Therapies along with companies
By Product Type
By Stage
By Route of Administration
By Molecule Type
By Mechanism of Action
By Targets
Contact Here for More Information @ NASH Pipeline Assessment
Scope of NASH Pipeline Report
Following is the Table of Content of the NASH Pipeline Report
1 | Report Introduction |
2 | Non-Alcoholic Steatohepatitis (NASH) |
3 | Non-Alcoholic Steatohepatitis (NASH) Current Treatment Patterns |
4 | Non-Alcoholic Steatohepatitis (NASH) – DelveInsight’s Analytical Perspective |
5 | Therapeutic Assessment |
6 | Non-Alcoholic Steatohepatitis (NASH) Late Stage Products (Phase-III) |
7 | Non-Alcoholic Steatohepatitis (NASH) Mid Stage Products (Phase-II) |
8 | Early Stage Products (Phase-I) |
9 | Pre-clinical Products and Discovery Stage Products |
10 | Inactive Products |
11 | Dormant Products |
12 | Non-Alcoholic Steatohepatitis (NASH) Discontinued Products |
13 | Non-Alcoholic Steatohepatitis (NASH) Product Profiles |
14 | Non-Alcoholic Steatohepatitis (NASH) Key Companies |
15 | Non-Alcoholic Steatohepatitis (NASH) Key Products |
16 | Dormant and Discontinued Products |
17 | Non-Alcoholic Steatohepatitis (NASH) Unmet Needs |
18 | Non-Alcoholic Steatohepatitis (NASH) Future Perspectives |
19 | Non-Alcoholic Steatohepatitis (NASH) Analyst Review |
20 | Appendix |
21 | Report Methodology |
Know more of what’s covered in the NASH Pipeline Assessment report
Key Questions Answered in the NASH report–
Request for demo @ NASH Pipeline and get a walk-through of our report
Related Reports
DelveInsight’ s Uncontrolled Bleeding Market Insights, Epidemiology and Market Forecast – 2030 report.
Post-Operative Nausea & Vomiting Market
DelveInsight’ s Postoperative Nausea & Vomiting Market Insights, Epidemiology and Market Forecast – 2030 report.
Heavy Menstrual Bleeding Market
DelveInsight’ s Heavy Menstrual Bleeding Market Insights, Epidemiology and Market Forecast – 2030 report.
Visit on our blog section-
About DelveInsight
DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.